
The recommendation is backed by data from the phase 3 LITESPARK-011 trial.
Dr. Primo Lara, Jr., executive associate dean for Cancer Programs, School of Medicine, at UC Davis Comprehensive Cancer Center, highlights the need for personalized medicine using multidisciplinary care for patients with renal cell carcinoma.